Quick answer : Ketamine reduces suicidal ideation significantly faster than any standard antidepressant. In clinical studies, measurable reductions in suicidal thinking have been documented within 40 minutes of a single IV infusion, before antidepressant effects have even developed. This rapid action makes ketamine uniquely valuable for patients in acute psychological crisis.
I want to start this one by naming something that often goes unsaid in conversations about psychiatric crisis care.
Standard antidepressants often take several weeks to produce their full effect. Sometimes they take longer.
For someone experiencing active suicidal ideation, that timeline can create a serious clinical challenge. A person in acute crisis may need help now, while a newly prescribed antidepressant may take weeks to show whether it will provide enough relief.
Ketamine works differently. Research has found that ketamine can reduce suicidal ideation rapidly in some patients, sometimes within hours. Understanding what the research shows can help patients and families have more informed conversations about treatment options.
In 2019, the FDA approved Spravato (esketamine) nasal spray for treatment-resistant depression in adults.
In 2020, the FDA added an indication for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. The current FDA label specifies that patients should receive Spravato alongside an oral antidepressant.
That approval represents an important development in the treatment of depression with acute suicidal ideation.
However, there is an important distinction to understand. The FDA label states that Spravato’s effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. It also states that Spravato does not replace hospitalization when hospitalization is clinically necessary.
In other words, Spravato can play a role in treatment for certain patients with MDD and acute suicidal ideation or behavior. It does not function as a standalone treatment for an immediate suicide crisis.
When someone is in acute distress, speed matters.
Research has repeatedly examined ketamine’s ability to reduce suicidal ideation rapidly. One study found significant reductions in suicidal ideation within 40 minutes of a single IV ketamine infusion in patients with treatment-resistant depression.
A 2018 randomized clinical trial also found that ketamine rapidly reduced suicidal thoughts in patients with major depressive disorder.
Other randomized trials have continued to examine ketamine for acute suicidal ideation. Results support a rapid effect in some patients, although the response varies and ketamine does not eliminate the need for ongoing psychiatric care.
This creates an important difference from traditional antidepressant treatment.
Starting sertraline or escitalopram today may require several weeks to determine whether the medication provides adequate relief. Ketamine can produce changes much sooner in some patients.
That speed can matter when someone is experiencing severe depression and suicidal thoughts.
Suicidal ideation can involve several overlapping changes in mood, cognition, attention, and emotional processing.
Severe depression can increase rumination and hopelessness. It can also narrow a person’s ability to imagine alternatives to their current circumstances. These changes can make emotional pain feel permanent and impossible to escape.
Ketamine acts differently from traditional antidepressants. It blocks NMDA receptors and affects the brain’s glutamate system. Researchers believe that downstream changes in synaptic signaling and neuroplasticity contribute to ketamine’s rapid antidepressant effects.
Brain-imaging and other research also suggest that ketamine can influence neural circuits involved in mood, self-referential thinking, and emotional processing. Researchers continue to study exactly how these changes relate to reductions in suicidal ideation.
The important point is that ketamine does not simply work by sedating someone.
Its therapeutic effects involve changes in brain signaling and may create a period in which psychological and behavioral patterns become more flexible.
If you are currently experiencing suicidal thoughts with intent or feel that you may act on them, seek immediate help.
Call or text 988, the Suicide & Crisis Lifeline, or go to the nearest emergency department. If you face an immediate danger, call 911 or have someone take you to the emergency room.
Ketamine treatment at an outpatient clinic is not a substitute for emergency psychiatric care.
The FDA specifically states that Spravato does not eliminate the need for hospitalization when hospitalization is clinically warranted.
If you or someone you love has experienced repeated psychiatric crises, this may be a conversation worth having with a qualified physician or mental health professional.
This can include people who:
Experience recurrent suicidal ideation alongside severe depression
Have not responded adequately to multiple antidepressant treatments
Have experienced repeated emergency room visits or psychiatric hospitalizations
Have treatment-resistant depression
Need an evaluation for whether ketamine or Spravato may fit into a broader treatment plan
Ketamine and Spravato offer different treatment approaches, and not every patient is an appropriate candidate.
At our Cardiff and Newport Beach clinics, we evaluate patients with histories of suicidal ideation carefully. We consider the severity of symptoms, previous treatments, current medications, safety concerns, and the level of care the patient needs.
If outpatient ketamine treatment appears appropriate, we can explain why and discuss the available options. If someone needs a higher level of psychiatric care first, that comes before outpatient treatment.
The goal is not simply to provide another treatment. The goal is to determine what level of care can provide the safest and most appropriate path forward.
Spravato (esketamine) — the intranasal formulation — has FDA approval specifically for major depressive disorder with acute suicidal ideation or behavior. That’s an explicit regulatory indication, not an off-label use. IV ketamine doesn’t carry that specific FDA label, but the clinical evidence for rapid anti-suicidal effects is substantial and has been replicated across multiple studies. The FDA approval matters for insurance coverage and for signaling that the evidence for Spravato cleared a very high regulatory bar for this specific use case.
If someone is in immediate danger — expressing intent, has a plan, or has means available — call 988 or go to the ER first. That’s not us deflecting; that’s the honest appropriate response to acute crisis. Where Seaside Ketamine becomes relevant is in the period after acute stabilization, or for patients who are in a chronic cycle of suicidal ideation that has not responded to standard antidepressants and ongoing psychiatric care. That’s the gap ketamine is specifically positioned to address. Call us once the immediate safety is managed and we’ll talk through what a thoughtful next step looks like.
Yes, both locations are certified Spravato treatment sites. For patients with the MDD-SI indication, Spravato has a specific insurance pathway — generally the same prior authorization process as the TRD indication, with documentation of the acute suicidal ideation as part of the clinical record. Coverage varies by plan, but most major commercial insurers, Medicare, and Medi-Cal have established Spravato coverage. We assist with verification and prior authorization before beginning treatment. Call either location directly and we’ll walk you through it.
